1. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
- Author
-
Elaine W. Lamirande, Marisa St. Claire, Brian R. Murphy, Peter L. Collins, William R. Elkins, Alexander Bukreyev, Ursula J. Buchholz, Kanta Subbarao, and Leatrice Vogel
- Subjects
business.industry ,Viral Vaccine ,viruses ,fungi ,virus diseases ,General Medicine ,medicine.disease_cause ,Virology ,Article ,Vaccination ,body regions ,Human Parainfluenza Virus ,Immunization ,Immunity ,Immunology ,medicine ,Viral shedding ,business ,skin and connective tissue diseases ,Coronavirus ,Parainfluenza Vaccines - Abstract
Summary Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus—SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease. Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5–8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.
- Published
- 2004